ArticleMolecular vision2025
Poor glycemic control impairs recovery from central retinal vein occlusion.
Article in Molecular vision, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the association between suboptimal glycemic control and central macular thickness in central retinal vein occlusion patients over a 1-year follow-up period. Methods: This retrospective cohort study included adult patients with central retinal vein occlusion diagnosed at the Helsinki University Hospital, Finland, with HbA1c levels measured within 6 months before or at diagnosis. Patients were divided into two groups: those with good (≤42 mmol/mol) and poor glycemic control (>42 mmol/mol). Central macular thickness and best-corrected visual acuity were assessed at baseline, 3 months, and 1 year. Results: Among 40 patients, 10 had suboptimal glycemic control. At 3 months and 1 year, central macular thickness was significantly higher in the poor glycemic control group compared with the good glycemic control group (367.0 ± 43.3 µm vs. 288.2 ± 36.6 µm, Conclusions: Poor glycemic control in patients with central retinal vein occlusion is associated with greater central macular thickness at both 3 months and 1 year. These findings emphasize the importance of optimal glycemic control to improve retinal outcomes in central retinal vein occlusion.
Indexed as
Identifiers
41867374PMC13002337What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.